Elucidating the specific pharmacological mechanism of motion (MOA) of naturally transpiring compounds can be complicated. Whilst Tarselli et al. (sixty) designed the 1st de novo synthetic pathway to conolidine and showcased that this naturally occurring compound correctly suppresses responses to each chemically induced and inflammation-derived sore